0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > 4-1BB

4-1BB

Brief Information

Name:Tumor necrosis factor receptor superfamily member 9
Target Synonym:TNFRSF9,T-cell antigen ILA,ILA,T-Cell Antigen 4-1BB Homolog,4-1BB Ligand Receptor,CD137 Antigen,CDw137,CD137,Tumor Necrosis Factor Receptor Superfamily, Member 9,Tumor Necrosis Factor Receptor Superfamily Member 9,Homolog Of Mouse 4-1BB,Receptor Protein 4
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Phase 2 Clinical

Licensing

Project item Indications Research phase Cooperation demands
BMS21009 Tumors such as breast cancer, bladder cancer, NSCLC,DLBCL. Pre-IND application Project authorization, transfer or co-development. (project’s company is seeking for external cooperation to accelate drug research and development.)

Product ListCompare or Buy

Part of Bioactivity data

41B-H5256-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Human 4-1BB, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. 41B-H5256) can bind to 293T cells overexpressing Human 4-1BBL. The concentration of 4-1BB used is 0.03 μg/mL (Routinely tested).

41B-H82F7-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human 4-1BB, Fc,Avitag (Cat. No. 41B-H82F7) can bind to 293T cells overexpressing Human 4-1BBL. The concentration of 4-1BB used is 0.3 μg/mL (Routinely tested).

41B-H82E4-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human 4-1BB (87-186), His,Avitag (Cat. No. 41B-H82E4) captured on Biotin CAP - Series S sensor Chip can bind Utomilumab with an affinity constant of 0.452 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

41B-H82E6-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human 4-1BB Protein, His,Avitag (Cat. No. 41B-H82E6) captured on Biotin CAP-Series S sensor Chip can bind anti 4-1BB mAb with an affinity constant of 0.158 nM as determined in a SPR assay (Biacore T200) (Routinely tested) .

Synonym Name

TNFRSF9,4-1BB,CD137,CDw137,ILA

Background

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RG-7827 RG-7827; FAP-4-1BBL; FAP-4-1BBL FP Phase 1 Clinical F. Hoffmann-La Roche Ltd Neoplasms Details
FS-120 FS-120 Phase 1 Clinical F-Star Neoplasms; Neoplasm Metastasis Details
INBRX-105 INBRX-105 Phase 1 Clinical Inhibrx Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Esophageal adenocarcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
CTX-471 CTX-471 Phase 1 Clinical Compass Therapeutics LLC Neoplasm Metastasis Details
ATOR-1017 ATOR-1017 Phase 1 Clinical Alligator Bioscience Neoplasms; Neoplasm Metastasis Details
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
MCLA-145 MCLA-145 Phase 1 Clinical Incyte Corp, Merus Neoplasms Details
AGEN-2373 AGEN-2373 Phase 1 Clinical Agenus Inc Neoplasms Details
Urelumab BMS-66513; BMS-663513 Phase 2 Clinical Bristol-Myers Squibb Company Lymphoma, B-Cell; Head and Neck Neoplasms; Solid tumours; Neoplasms; Multiple Myeloma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell Details
Delolimogene mupadenorepvec LOAd-703 Phase 2 Clinical Lokon Pharma, Uppsala University Biliary Tract Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma Details
Cinrebafusp alfa PRS-343 Phase 1 Clinical Pieris Pharmaceuticals Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms Details
ADG-106 ADG-106 Phase 2 Clinical Adagene (Suzhou) Ltd Solid tumours; Lymphoma, Non-Hodgkin Details
Utomilumab PF-2566; PF-5082566; PF-05082566 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Solid tumours; Ovarian Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Breast Neoplasms; Lymphoma, Follicular; Colorectal Neoplasms; Oropharyngeal Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma Details
ND-021 ND-021; NM21-1480; CS-2006; CS2006 Phase 2 Clinical Numab Therapeutics Ag Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
LVGN-6051 LVGN-6051 Phase 1 Clinical Lyvgen Biopharma(HK)Ltd Neoplasms Details
GEN-1042 GEN-1042; BNT-312 Phase 2 Clinical Genmab Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
MP-0310 MP-0310; AMG-506 Phase 1 Clinical Molecular Partners Ag Solid tumours Details
HOT-1030 HOT-1030 Phase 1 Clinical Solid tumours Details
QLF31907 QLF31907; QLF-31907 Qilu Pharmaceutical Co Ltd Details
IBI319 IBI-319 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Glioma; Neoplasm Metastasis Details
PE-0116 PE-0116 Phase 1 Clinical Shanghai Huaiyue Biotechnology Co Ltd Solid tumours Details
GNC-038 GNC-038 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
TJ-CD4B TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721 Phase 1 Clinical Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis Details
ABL-503 ABL-503; TJ-L14B/ABL503; ABL503 Phase 1 Clinical Abl Bio Inc Solid tumours Details
ES101 ES101 Phase 2 Clinical Inhibrx Solid tumours; Thoracic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung Details
RO-7122290 RO-7122290 Phase 2 Clinical F. Hoffmann-La Roche Ltd Colorectal Neoplasms Details
FS-222 FS-222 Phase 1 Clinical F-star Beta Ltd Neoplasm Metastasis Details
GNC-035 quadr-specific antibody(baili) GNC-035 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours Details
GEN-1046 GEN1046; PD-L1x4-1BB; DuoBody-PD-L1x4-1BB Phase 2 Clinical Biontech Se, Genmab Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
EU-101 EU-101; NOV-1801 Phase 2 Clinical Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop